| US 7,375,114 B2 | ||
| Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | ||
| Daniel Marquess, Half Moon Bay, Calif. (US); Paul R. Fatheree, San Francisco, Calif. (US); S. Derek Turner, San Francisco, Calif. (US); Daniel D. Long, San Francisco, Calif. (US); Seok-Ki Choi, Palo Alto, Calif. (US); Adam A. Goldblum, San Francisco, Calif. (US); and Daniel Genov, San Francisco, Calif. (US) | ||
| Assigned to Theravance, Inc., South San Francisco, Calif. (US) | ||
| Filed on Apr. 06, 2005, as Appl. No. 11/100,113. | ||
| Claims priority of provisional application 60/560076, filed on Apr. 07, 2004. | ||
| Prior Publication US 2005/0228014 A1, Oct. 13, 2005 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. A01N 43/42 (2006.01); A61K 31/44 (2006.01); C07D 451/02 (2006.01); C07D 401/00 (2006.01); C07D 409/00 (2006.01) | ||
| U.S. Cl. 514—304 [546/124; 546/126] | 17 Claims |
1. A compound of formula (I):
 wherein:
R1 is hydrogen, halo, hydroxy, C1-4alkyl, or C1-4alkoxy;
R2 is C3-4alkyl, or C3-6cycloalkyl;
R3 is hydrogen or C1-3alkyl;
R4 is —S(O)2R6 or —C(O)R7;
R5 is hydrogen, C1-3alkyl, C2-3alkyl substituted with —OH or C1-3alkoxy, or —CH2-pyridyl;
R6 is C1-3alkyl;
or, R5 and R6 taken together form C3-4alkylenyl; and
R7 is hydrogen, C1-3alkyl, or pyridyl;
or a pharmaceutically-acceptable salt or stereoisomer thereof.
|